Metabolic Dysfunction-Associated Fatty Liver Disease, Thyroid Dysfunction
Conditions
Brief summary
This study aims to evaluate the prevalence of thyroid dysfunction and its association with metabolic dysfunction-associated fatty liver disease.
Detailed description
One of the most common causes of chronic liver diseases worldwide is metabolic dysfunction-associated fatty liver disease (MAFLD), which affects about 30% of adults. Thyroid hormones are critical in maintaining metabolic homeostasis throughout life and are intimately linked to the liver. Dysfunctions of the thyroid gland have been implicated as one of the most important risk factors of MAFLD due to its important role in the hepatic synthesis of fatty acid and cholesterol. Maintaining liver metabolism requires thyroid function to be normal, while thyroid disorders may lead to liver disease progression.
Interventions
DEVICEFibroscan
Fibroscan will be used to assess the stages of fibrosis and steatosis using Dimensional ultrasound TE (transient elastography). Dimensional ultrasound TE (transient elastography) will be used for staging liver fibrosis and steatosis by measuring the velocity of a low frequency (50 Hz) elastic shear wave propagating through the liver.
Sponsors
Tanta University
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age ≥ 18 years. * Both sexes. * Patients with metabolic dysfunction-associated fatty liver disease (MAFLD).
Exclusion criteria
* History of thyroid disease or treatment (e.g., thyroid nodules, thyroid cancer, hypothyroidism, and hyperthyroidism). * Patients with alcoholic liver disease take more than 40g of alcohol (or four units) per day. * Viral hepatitis. * Pregnant women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Level of free triiodothyronine (FT3) | After the sample is taken (up to 5 minutes) | Free triiodothyronine (FT3) will be measured using chemiluminescent immunoassay analysis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Level of free thyroxine (FT4) | After the sample is taken (up to 5 minutes) | Free thyroxine (FT4) will be measured using chemiluminescent immunoassay analysis. |
| Level of thyroid stimulating hormone | After the sample is taken (up to 5 minutes) | Thyroid stimulating hormone will be measured using chemiluminescent immunoassay analysis. |
| Relation between gender and thyroid function | After the sample is taken (up to 5 minutes) | Relation between gender and thyroid function will be assessed. |
| Correlation between metabolic data and thyroid function tests | After the sample is taken (up to 5 minutes) | Correlation between metabolic data and thyroid function tests will be assessed. |
Countries
Egypt
Contacts
Primary ContactShimaa A Meshaal, MD
Outcome results
None listed